{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:48:45Z","timestamp":1786495725392,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hereditary transthyretin amyloidosis is a rapidly progressive and lethal disease. Thanks to the increasing number of disease-modifying treatments, prognosis has improved significantly. However, new challenges regarding treatment response and when to change treatment remain unanswered. The objective of this study was to evaluate rationales for treatment switches from the past and to formulate learnings for future management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this retrospective single center study, we analyzed real-world data of 13 patients with hereditary transthyretin amyloidosis undergoing single or multiple treatment switches before January 2024. Data involved demographic characteristics as well as reasons for treatment switches in a descriptive and exploratory manner. Available amyloid specific therapies during the study period included tafamidis 20\u00a0mg, tafamidis 61\u00a0mg, patisiran, inotersen and vutrisiran.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Switches from tafamidis 20\u00a0mg were most frequently due to disease progression (83.3%). Patisiran transitions predominantly occurred following vutrisiran\u2019s approval, driven by preference for subcutaneous administration and extended dosing intervals (65.0%). Two cases of switches from inotersen were both associated with severe adverse effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In this study, reasons for treatment switches were manifold, encompassing disease progression, the occurrence of adverse events, patient preferences and\/or the availability of newly approved drugs. Hence, multidimensional consideration of these reasons remains pivotal in guiding the subsequent choice of medication in particular and managing hereditary transthyretin amyloidosis in general.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s42466-025-00428-6","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T12:15:11Z","timestamp":1757679311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world treatment management in hereditary transthyretin amyloidosis \u2013 an experience report and proposal for therapy switch decision criteria"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4929-5790","authenticated-orcid":false,"given":"Duc Chu","family":"Dieu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8711-5526","authenticated-orcid":false,"given":"Helena F.","family":"Pernice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5170-3722","authenticated-orcid":false,"given":"Harisa","family":"Muratovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9393-5512","authenticated-orcid":false,"given":"Paul J.","family":"Wetzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-2159","authenticated-orcid":false,"given":"Gina","family":"Barzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5683-2891","authenticated-orcid":false,"given":"Nicolas W.","family":"Wieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0805-3129","authenticated-orcid":false,"given":"Stefanie M.","family":"Werhahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3811-7920","authenticated-orcid":false,"given":"Bettina","family":"Heidecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0987-8007","authenticated-orcid":false,"given":"Sebastian","family":"Spethmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6013-0072","authenticated-orcid":false,"given":"Katrin","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"issue":"7","key":"428_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams, D., Koike, H., Slama, M., & Coelho, T. (2019). Hereditary transthyretin amyloidosis: A model of medical progress for A fatal disease. Nat Rev Neurol, 15(7), 387\u2013404. https:\/\/doi.org\/10.1038\/s41582-019-0210-4","journal-title":"Nat Rev Neurol"},{"key":"428_CR2","doi-asserted-by":"publisher","first-page":"1242815","DOI":"10.3389\/fneur.2023.1242815","volume":"14","author":"L Poli","year":"2023","unstructured":"Poli, L., Labella, B., Cotti Piccinelli, S., Caria, F., Risi, B., Damioli, S., Padovani, A., & Filosto, M. (2023). Hereditary transthyretin amyloidosis: A comprehensive review with A focus on peripheral neuropathy. Frontiers in Neurology, 14, 1242815. https:\/\/doi.org\/10.3389\/fneur.2023.1242815","journal-title":"Frontiers in Neurology"},{"issue":"2","key":"428_CR3","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s40120-021-00258-z","volume":"10","author":"M Waddington-Cruz","year":"2021","unstructured":"Waddington-Cruz, M., Wixner, J., Amass, L., Kiszko, J., Chapman, D., & Ando, Y. (2021). Characteristics of patients with Late- vs. Early-Onset Val30Met transthyretin amyloidosis from the transthyretin amyloidosis outcomes survey (THAOS). Neurol Ther, 10(2), 753\u2013766. https:\/\/doi.org\/10.1007\/s40120-021-00258-z","journal-title":"Neurol Ther"},{"key":"428_CR4","unstructured":"Sekijima, Y., & Nakamura, K. (1993). Hereditary Transthyretin Amyloidosis, in GeneReviews(\u00ae), M.P. Adam, J. Feldman, G.M. Mirzaa, R.A. Pagon, S.E. Wallace, and A. Amemiya, Editors. University of Washington, Seattle Copyright \u00a9 1993\u20132024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.: Seattle (WA)."},{"key":"428_CR5","doi-asserted-by":"publisher","unstructured":"Gonzalez-Duarte, A., & Ulloa-Aguirre, A. (2021). A brief journey through protein misfolding in transthyretin amyloidosis (ATTR amyloidosis). International Journal of Molecular Sciences, 22(23). https:\/\/doi.org\/10.3390\/ijms222313158","DOI":"10.3390\/ijms222313158"},{"key":"428_CR6","unstructured":"Jain, A., & Zahra, F. (2024). Transthyretin Amyloid Cardiomyopathy (ATTR-CM), in StatPearls. StatPearls Publishing Copyright \u00a9 2024, StatPearls Publishing LLC.: Treasure Island (FL)."},{"issue":"10","key":"428_CR7","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1161\/circresaha.121.318187","volume":"128","author":"JM Griffin","year":"2021","unstructured":"Griffin, J. M., Rosenblum, H., & Maurer, M. S. (2021). Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ Res, 128(10), 1554\u20131575. https:\/\/doi.org\/10.1161\/circresaha.121.318187","journal-title":"Circ Res"},{"issue":"21","key":"428_CR8","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1212\/wnl.0000000000003362","volume":"87","author":"H Koike","year":"2016","unstructured":"Koike, H., Ikeda, S., Takahashi, M., Kawagashira, Y., Iijima, M., Misumi, Y., Ando, Y., Ikeda, S. I., Katsuno, M., & Sobue, G. (2016). Schwann cell and endothelial cell damage in transthyretin Familial amyloid polyneuropathy. Neurology, 87(21), 2220\u20132229. https:\/\/doi.org\/10.1212\/wnl.0000000000003362","journal-title":"Neurology"},{"issue":"7","key":"428_CR9","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/archneur.62.7.1057","volume":"62","author":"Y Ando","year":"2005","unstructured":"Ando, Y., Nakamura, M., & Araki, S. (2005). Transthyretin-related Familial amyloidotic polyneuropathy. Archives of Neurology, 62(7), 1057\u20131062. https:\/\/doi.org\/10.1001\/archneur.62.7.1057","journal-title":"Archives of Neurology"},{"key":"428_CR10","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-Valle, F., Casasnovas-Pons, C., Romero-Acebal, M., & Gal\u00e1n-D\u00e1vila, L. (2024). Evaluation of autonomic dysfunction in hereditary transthyretin amyloidosis. Neurolog\u00eda, Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0213485324002354https:\/\/doi.org\/10.1016\/j.nrl.2023.04.010","DOI":"10.1016\/j.nrl.2023.04.010"},{"key":"428_CR11","unstructured":"Coutinho, P. M., Silva, A. M., Lopes, J., Resende, P-E-A., Silva, A. M., Resende, L. A. L., Silva, A. M.d., Filho, J. D., & Barbosa (Eds.). (1980). A.L.R. Forty years of experience with type I amyloid neuropathy. Review of 483 cases."},{"key":"428_CR12","doi-asserted-by":"publisher","unstructured":"Dohrn, M., Auer-Grumbach, M., Baron, R., Birklein, F., Escolano, F., Geber, C., Grether, N., Hagenacker, T., Hund, E., Sachau, J., Schilling, M., Schmidt, J., Schulte-Mattler, W., Sommer, C., Weiler, M., Wunderlich, G., & Hahn, K. (2021). Chance or challenge, spoilt for choice? New recommendations on diagnostic and Therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: The german\/austrian position and review of The literature. Journal of Neurology, 268. https:\/\/doi.org\/10.1007\/s00415-020-09962-6","DOI":"10.1007\/s00415-020-09962-6"},{"issue":"Suppl 1","key":"428_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10286-019-00628-6","volume":"29","author":"L Obici","year":"2019","unstructured":"Obici, L., & Suhr, O. B. (2019). Diagnosis and treatment of Gastrointestinal dysfunction in hereditary TTR amyloidosis. Clinical Autonomic Research, 29(Suppl 1), 55\u201363. https:\/\/doi.org\/10.1007\/s10286-019-00628-6","journal-title":"Clinical Autonomic Research"},{"key":"428_CR14","doi-asserted-by":"publisher","unstructured":"Ferraro, P. M., D\u2019Ambrosio, V., Di Paolantonio, A., Guglielmino, V., Calabresi, P., Sabatelli, M., & Luigetti, M. (2021). Renal involvement in hereditary transthyretin amyloidosis: An Italian Single-Centre experience. Brain Sci, 11(8). https:\/\/doi.org\/10.3390\/brainsci11080980","DOI":"10.3390\/brainsci11080980"},{"issue":"2","key":"428_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3109\/13506129.2015.1015678","volume":"22","author":"JM Beir\u00e3o","year":"2015","unstructured":"Beir\u00e3o, J. M., Malheiro, J., Lemos, C., Beir\u00e3o, I., Costa, P., & Torres, P. (2015). Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: A review of 513 cases. Amyloid, 22(2), 117\u2013122. https:\/\/doi.org\/10.3109\/13506129.2015.1015678","journal-title":"Amyloid"},{"issue":"1","key":"428_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/13506129.2022.2128331","volume":"30","author":"Y Takahashi","year":"2023","unstructured":"Takahashi, Y., Oguchi, K., Mochizuki, Y., Takasone, K., Ezawa, N., Matsushima, A., Katoh, N., Yazaki, M., & Sekijima, Y. (2023). Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis. Amyloid, 30(1), 109\u2013118. https:\/\/doi.org\/10.1080\/13506129.2022.2128331","journal-title":"Amyloid"},{"key":"428_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40478-015-0216-0","volume":"3","author":"JL Ziskin","year":"2015","unstructured":"Ziskin, J. L., Greicius, M. D., Zhu, W., Okumu, A. N., Adams, C. M., & Plowey, E. D. (2015). Neuropathologic analysis of Tyr69His TTR variant meningovascular amyloidosis with dementia. Acta Neuropathol Commun, 3, 43. https:\/\/doi.org\/10.1186\/s40478-015-0216-0","journal-title":"Acta Neuropathol Commun"},{"issue":"11","key":"428_CR18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., Drachman, B. M., Shah, S. J., Hanna, M., Judge, D. P., Barsdorf, A. I., Huber, P., Patterson, T. A., Riley, S., Schumacher, J., Stewart, M., Sultan, M. B., & Rapezzi, C. (2018). Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine, 379(11), 1007\u20131016. https:\/\/doi.org\/10.1056\/NEJMoa1805689","journal-title":"New England Journal of Medicine"},{"key":"428_CR19","doi-asserted-by":"publisher","unstructured":"Adams, D., Tournev, I. L., Taylor, M. S., Coelho, T., Plant\u00e9-Bordeneuve, V., Berk, J. L., Gonz\u00e1lez-Duarte, A., Gillmore, J. D., Low, S. C., Sekijima, Y., Obici, L., Chen, C., Badri, P., Arum, S. M., Vest, J., & Polydefkis, M. (2023). Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid, 30(1): pp. 18\u201326 Available from: https:\/\/doi.org\/10.1080\/13506129.2022.2091985 DOI: 10.1080\/13506129.2022.2091985.","DOI":"10.1080\/13506129.2022.2091985"},{"issue":"1","key":"428_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Plant\u00e9-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., Scheinberg, M., Brannagan, T. H. 3rd, Litchy, W. J., Whelan, C., Drachman, B. M., Adams, D., Heitner, S. B., Concei\u00e7\u00e3o, I., Schmidt, H. H., Vita, G., Campistol, J. M., Gamez, J., Gorevic, P. D., Gane, E., Shah, A. M., Solomon, S. D., Monia, B. P., Hughes, S. G., Kwoh, T. J., McEvoy, B. W., Jung, S. W., Baker, B. F., Ackermann, E. J., Gertz, M. A., & Coelho, T. (2018). Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine, 379(1), 22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"428_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","volume":"17","author":"D Adams","year":"2017","unstructured":"Adams, D., Suhr, O. B., Dyck, P. J., Litchy, W. J., Leahy, R. G., Chen, J., Gollob, J., & Coelho, T. (2017). Trial design and rationale for APOLLO, a phase 3, placebo-controlled study of Patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. Bmc Neurology, 17(1), 181. https:\/\/doi.org\/10.1186\/s12883-017-0948-5","journal-title":"Bmc Neurology"},{"issue":"15","key":"428_CR22","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho, T., Marques, W. Jr., Dasgupta, N. R., Chao, C. C., Parman, Y., Fran\u00e7a, M. C. Jr., Guo, Y. C., Wixner, J., Ro, L. S., Calandra, C. R., Kowacs, P. A., Berk, J. L., Obici, L., Barroso, F. A., Weiler, M., Concei\u00e7\u00e3o, I., Jung, S. W., Buchele, G., Brambatti, M., Chen, J., Hughes, S. G., Schneider, E., Viney, N. J., Masri, A., Gertz, M. R., Ando, Y., Gillmore, J. D., Khella, S., Dyck, P. J. B., & Cruz, W. (2023). M Eplontersen for Hereditary Transthyretin Amyloidosis with Polyneuropathy Jama, 330(15): 1448\u20131458 https:\/\/doi.org\/10.1001\/jama.2023.18688","journal-title":"M Eplontersen for Hereditary Transthyretin Amyloidosis with Polyneuropathy Jama"},{"issue":"2","key":"428_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore, J. D., Judge, D. P., Cappelli, F., Fontana, M., Garcia-Pavia, P., Gibbs, S., Grogan, M., Hanna, M., Hoffman, J., Masri, A., Maurer, M. S., Nativi-Nicolau, J., Obici, L., Poulsen, S. H., Rockhold, F., Shah, K. B., Soman, P., Garg, J., Chiswell, K., Xu, H., Cao, X., Lystig, T., Sinha, U., & Fox, J. C. (2024). Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. New England Journal of Medicine, 390(2), 132\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa2305434","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"428_CR24","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Plant\u00e9-Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Concei\u00e7\u00e3o, I. M., Schmidt, H. H., Trigo, P., Kelly, J. W., Labaudini\u00e8re, R., Chan, J., Packman, J., Wilson, A., & Grogan, D. R. (2012). Tafamidis for transthyretin Familial amyloid polyneuropathy: A randomized, controlled trial. Neurology, 79(8), 785\u2013792. https:\/\/doi.org\/10.1212\/WNL.0b013e3182661eb1","journal-title":"Neurology"},{"issue":"24","key":"428_CR25","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk, J. L., Suhr, O. B., Obici, L., Sekijima, Y., Zeldenrust, S. R., Yamashita, T., Heneghan, M. A., Gorevic, P. D., Litchy, W. J., Wiesman, J. F., Nordh, E., Corato, M., Lozza, A., Cortese, A., Robinson-Papp, J., Colton, T., Rybin, D. V., Bisbee, A. B., Ando, Y., Ikeda, S., Seldin, D. C., Merlini, G., Skinner, M., Kelly, J. W., & Dyck, P. J. (2013). Repurposing diflunisal for Familial amyloid polyneuropathy: A randomized clinical trial. Jama, 310(24), 2658\u20132667. https:\/\/doi.org\/10.1001\/jama.2013.283815","journal-title":"Jama"},{"issue":"6","key":"428_CR26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O\u2019Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D. (2021). CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine, 385(6), 493\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2107454","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"428_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","volume":"389","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia, P., Aus dem Siepen, F., Donal, E., Lairez, O., van der Meer, P., Kristen, A. V., Mercuri, M. F., Michalon, A., Frost, R. J. A., Grimm, J., Nitsch, R. M., Hock, C., Kahr, P. C., & Damy, T. (2023). Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. New England Journal of Medicine, 389(3), 239\u2013250. https:\/\/doi.org\/10.1056\/NEJMoa2303765","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"428_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams, D., Gonzalez-Duarte, A., O\u2019Riordan, W. D., Yang, C. C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., Lin, K. P., Vita, G., Attarian, S., Plant\u00e9-Bordeneuve, V., Mezei, M. M., Campistol, J. M., Buades, J., Brannagan, T. H. 3rd, Kim, B. J., Oh, J., Parman, Y., Sekijima, Y., Hawkins, P. N., Solomon, S. D., Polydefkis, M., Dyck, P. J., Gandhi, P. J., Goyal, S., Chen, J., Strahs, A. L., Nochur, S. V., Sweetser, M. T., Garg, P. P., Vaishnaw, A. K., Gollob, J. A., & Suhr, O. B. (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine, 379(1), 11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"428_CR29","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/jnc.15233","volume":"156","author":"MF Dohrn","year":"2021","unstructured":"Dohrn, M. F., Ihne, S., Hegenbart, U., Medina, J., Z\u00fcchner, S. L., Coelho, T., & Hahn, K. (2021). Targeting transthyretin - Mechanism-based treatment approaches and future perspectives in hereditary amyloidosis. Journal of Neurochemistry, 156(6), 802\u2013818. https:\/\/doi.org\/10.1111\/jnc.15233","journal-title":"Journal of Neurochemistry"},{"key":"428_CR30","doi-asserted-by":"publisher","first-page":"116424","DOI":"10.1016\/j.jns.2019.116424","volume":"405","author":"PJB Dyck","year":"2019","unstructured":"Dyck, P. J. B., Gonz\u00e1lez-Duarte, A., Obici, L., Polydefkis, M., Wiesman, J. F., Antonino, I., Litchy, W. J., & Dyck, P. J. (2019). Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS\u2009+\u20097. Journal of the Neurological Sciences, 405, 116424. https:\/\/doi.org\/10.1016\/j.jns.2019.116424","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"428_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/jns5.12059","volume":"19","author":"EJ Vinik","year":"2014","unstructured":"Vinik, E. J., Vinik, A. I., Paulson, J. F., Merkies, I. S., Packman, J., Grogan, D. R., & Coelho, T. (2014). Norfolk QOL-DN: Validation of a patient reported outcome measure in transthyretin Familial amyloid polyneuropathy. Journal of the Peripheral Nervous System : Jpns, 19(2), 104\u2013114. https:\/\/doi.org\/10.1111\/jns5.12059","journal-title":"Journal of the Peripheral Nervous System : Jpns"},{"key":"428_CR32","doi-asserted-by":"publisher","unstructured":"Plant\u00e9-Bordeneuve, V., & Perrain, V. (2024). Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy. Expert Opinion on Drug Discovery, 19(4): pp. 393\u2013402 Available from: https:\/\/doi.org\/10.1080\/17460441.2024.2306843 DOI: 10.1080\/17460441.2024.2306843.","DOI":"10.1080\/17460441.2024.2306843"},{"issue":"1","key":"428_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","volume":"392","author":"M Fontana","year":"2025","unstructured":"Fontana, M., Berk, J. L., Gillmore, J. D., Witteles, R. M., Grogan, M., Drachman, B., Damy, T., Garcia-Pavia, P., Taubel, J., Solomon, S. D., Sheikh, F. H., Tahara, N., Gonz\u00e1lez-Costello, J., Tsujita, K., Morbach, C., Pozsonyi, Z., Petrie, M. C., Delgado, D., Van der Meer, P., Jabbour, A., Bondue, A., Kim, D., Azevedo, O., Poulsen, H., Yilmaz, S., Jankowska, A., Algalarrondo, E. A., Slugg, V., Garg, A., Boyle, P. P., Yureneva, K. L., Silliman, E., Yang, N., Chen, L., Eraly, J., Vest, S. A., J., and, & Maurer, M. S. (2025). Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. New England Journal of Medicine, 392(1), 33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2409134","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"428_CR34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-024-02008-5","volume":"84","author":"T Nie","year":"2024","unstructured":"Nie, T. (2024). Eplontersen: First approval. Drugs, 84(4), 473\u2013478. https:\/\/doi.org\/10.1007\/s40265-024-02008-5","journal-title":"Drugs"},{"issue":"26","key":"428_CR35","doi-asserted-by":"publisher","first-page":"15051","DOI":"10.1073\/pnas.93.26.15051","volume":"93","author":"GJ Miroy","year":"1996","unstructured":"Miroy, G. J., Lai, Z., Lashuel, H. A., Peterson, S. A., Strang, C., & Kelly, J. W. (1996). Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A, 93(26), 15051\u201315056. https:\/\/doi.org\/10.1073\/pnas.93.26.15051","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"428_CR36","doi-asserted-by":"publisher","first-page":"9629","DOI":"10.1073\/pnas.1121005109","volume":"109","author":"CE Bulawa","year":"2012","unstructured":"Bulawa, C. E., Connelly, S., Devit, M., Wang, L., Weigel, C., Fleming, J. A., Packman, J., Powers, E. T., Wiseman, R. L., Foss, T. R., Wilson, I. A., Kelly, J. W., & Labaudini\u00e8re, R. (2012). Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A, 109(24), 9629\u20139634. https:\/\/doi.org\/10.1073\/pnas.1121005109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"428_CR37","doi-asserted-by":"publisher","unstructured":"Schmidt, D., Osmanodja, B., Pfefferkorn, M., Graf, V., Raschke, D., Duettmann, W., Naik, M. G., Gethmann, C. J., Mayrdorfer, M., Halleck, F., Liefeldt, L., Glander, P., Staeck, O., Mallach, M., Peuker, M., & Budde, K. (2021). TBase - an integrated electronic health record and research database for kidney transplant recipients. Journal of Visualized Experiments : Jove, (170). https:\/\/doi.org\/10.3791\/61971","DOI":"10.3791\/61971"},{"issue":"6","key":"428_CR38","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1177\/193229680800200616","volume":"2","author":"EJ Vinik","year":"2008","unstructured":"Vinik, E. J., Paulson, J. F., Ford-Molvik, S. L., & Vinik, A. I. (2008). German-translated Norfolk quality of life (QOL-DN) identifies the same factors as the english version of the tool and discriminates different levels of neuropathy severity. Journal of Diabetes Science and Technology, 2(6), 1075\u20131086. https:\/\/doi.org\/10.1177\/193229680800200616","journal-title":"Journal of Diabetes Science and Technology"},{"issue":"12","key":"428_CR39","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.mayocp.2012.10.013","volume":"87","author":"DM Sletten","year":"2012","unstructured":"Sletten, D. M., Suarez, G. A., Low, P. A., Mandrekar, J., & Singer, W. (2012). COMPASS 31: A refined and abbreviated composite autonomic symptom score. Mayo Clinic Proceedings, 87(12), 1196\u20131201. https:\/\/doi.org\/10.1016\/j.mayocp.2012.10.013","journal-title":"Mayo Clinic Proceedings"},{"issue":"12","key":"428_CR40","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/ene.12225","volume":"20","author":"P Lozeron","year":"2013","unstructured":"Lozeron, P., Th\u00e9audin, M., Mincheva, Z., Ducot, B., Lacroix, C., & Adams, D. (2013). Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin Familial amyloid polyneuropathy. European Journal of Neurology, 20(12), 1539\u20131545. https:\/\/doi.org\/10.1111\/ene.12225","journal-title":"European Journal of Neurology"},{"issue":"8","key":"428_CR41","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1212\/wnl.0000000000001870","volume":"85","author":"D Adams","year":"2015","unstructured":"Adams, D., Coelho, T., Obici, L., Merlini, G., Mincheva, Z., Suanprasert, N., Bettencourt, B. R., Gollob, J. A., Gandhi, P. J., Litchy, W. J., & Dyck, P. J. (2015). Rapid progression of Familial amyloidotic polyneuropathy: A multinational natural history study. Neurology, 85(8), 675\u2013682. https:\/\/doi.org\/10.1212\/wnl.0000000000001870","journal-title":"Neurology"},{"issue":"2","key":"428_CR42","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00415-016-8337-3","volume":"264","author":"V Plant\u00e9-Bordeneuve","year":"2017","unstructured":"Plant\u00e9-Bordeneuve, V., Gorram, F., Salhi, H., Nordine, T., Ayache, S. S., Le Corvoisier, P., Azoulay, D., Feray, C., Damy, T., & Lefaucheur, J. P. (2017). Long-term treatment of transthyretin Familial amyloid polyneuropathy with tafamidis: A clinical and neurophysiological study. Journal of Neurology, 264(2), 268\u2013276. https:\/\/doi.org\/10.1007\/s00415-016-8337-3","journal-title":"Journal of Neurology"},{"key":"428_CR43","doi-asserted-by":"publisher","unstructured":"Cortese, A., Vita, G., Luigetti, M., Russo, M., Bisogni, G., Sabatelli, M., Manganelli, F., Santoro, L., Cavallaro, T., Fabrizi, G. M., Schenone, A., Grandis, M., Gemelli, C., Mauro, A., Pradotto, L. G., Gentile, L., Stancanelli, C., Lozza, A., Perlini, S., Piscosquito, G., Calabrese, D., Mazzeo, A., Obici, L., & Pareyson, D. (2016). Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. Journal of Neurology, 263(5): pp. 916\u2013924 Available from: https:\/\/doi.org\/10.1007\/s00415-016-8064-9","DOI":"10.1007\/s00415-016-8064-9"},{"issue":"9","key":"428_CR44","doi-asserted-by":"publisher","first-page":"e16384","DOI":"10.1111\/ene.16384","volume":"31","author":"C Labeyrie","year":"2024","unstructured":"Labeyrie, C., Merkel, M., Sethi, S., Popadic, L., Yang, H., Sweetser, M. T., Lin, H., & Adams, D. (2024). Effectiveness of Patisiran after switching from Tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy. European Journal of Neurology, 31(9), e16384. https:\/\/doi.org\/10.1111\/ene.16384","journal-title":"European Journal of Neurology"},{"key":"428_CR45","unstructured":"EMA Wainzua eplontersen. European Medicines Agency 2025 24.04.2025Abgerufen am: 10.05.2025; Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/wainzua"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-025-00428-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00428-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T16:03:21Z","timestamp":1757952201000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-025-00428-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["428"],"URL":"https:\/\/doi.org\/10.1186\/s42466-025-00428-6","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee Charit\u00e9 University Medicine, Berlin Germany as part of the Amyloidosis Register of the ACCB (EA1\/014\/020). All included patients have signed an informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors gave consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DCD and HM declare that they have no competing interests. HFP has received personal funding, travel support, and speaker fees by Alnylam Pharmaceuticals Inc. HP also received personal funding by Deutsche Gesellschaft f\u00fcr Muskelkranke (DGM) GmbH and Berlin Institute of Health (BIH) unrelated to this project. GB received speakers fee by Alnylam Pharmaceuticals Inc and Astra Zeneca GmbH, travel fees from Alnylam Pharmaceuticals and Intellia Therapeutics and reports scientific grants from Innovation Committee at the Federal Joint Committee (G-BA). SW has received travel support from Bayer Vital GmbH and Pfizer Pharma GmbH. BH is inventor on patents that use RNA for diagnosis of myocarditis. Patent protection is in process for MCG for diagnosis and measurement of therapy response in inflammatory cardiomyopathy and for cytokines for targeted therapy in inflammatory cardiomyopathy and heart failure. BH has received speaker fees from Pfizer and Astra Zeneca unrelated to this work. SS reports scientific grants from Innovation Committee at the Federal Joint Committee (G-BA), Pfizer Pharma GmbH, and Apple Inc.; Honoraria for lectures from Novartis Pharma GmbH, AstraZeneca GmbH, Pfizer Pharma GmbH, Alnylam Netherlands B.V., and Bayer Vital GmbH; travel fees from Pfizer Pharma GmbH, Alnylam Netherlands B.V., AstraZeneca GmbH, and Boehringer Ingelheim; Advisory fees from Novartis Pharma GmbH, Pfizer Pharma GmbH, Bayer Vital GmbH, Alnylam Netherlands B.V., and Bayer Vital GmbH. KH received financial reimbursement for consulting, advisory board activities, speaker fees and\/or contributions to congresses and travel support to attend scientific meetings by Akcea Therapeuticals Inc., Alnylam Pharmaceuticals Inc., Amicus, AstraZeneca, Bayer, BridgeBio, GSK, Hormosan, Takeda Pharmaceutical Inc., Pfizer Pharmaceuticals Inc., Purpose Pharma and Swedish Orphan Biovitrum Inc and ViiV Healthcare GmbH. KH further received research funding by the foundation Charit\u00e9 (BIH clinical fellow, BIH digital accelerator), Alnylam Pharmaceuticals Inc., and Pfizer Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}